about
Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.Inhibition of STAT3 activity re-activates anti-tumor immunity but fails to restore the immunogenicity of tumor cells in a B-cell lymphoma modelCombination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines.Fully human antibody exhibits pan-human leukocyte antigen-DR recognition and high in vitro/vivo efficacy against human leukocyte antigen-DR-positive lymphomas.Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells.
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Monoclonal antibody therapy of B cell lymphoma.
@ast
Monoclonal antibody therapy of B cell lymphoma.
@en
type
label
Monoclonal antibody therapy of B cell lymphoma.
@ast
Monoclonal antibody therapy of B cell lymphoma.
@en
prefLabel
Monoclonal antibody therapy of B cell lymphoma.
@ast
Monoclonal antibody therapy of B cell lymphoma.
@en
P2860
P356
P1476
Monoclonal antibody therapy of B cell lymphoma.
@en
P2093
Brian K Link
George J Weiner
P2860
P304
P356
10.1517/14712598.4.3.375
P407
P577
2004-03-01T00:00:00Z